Small molecule inhibitors that selectively abolish extrasynaptic NMDARs-induced glutamate neurotoxicity while preserving synaptic NMDARs effects on neuronal survival and memory.

A small molecule TwinF interface inhibitor that has shown preclinical proof-of-concept for treating amyotrophic lateral sclerosis (ALS) by reducing neurological scores and mortality in mouse models and protecting human ALS patient-derived brain organoids from glutamate neurotoxicity.